Cancer News and Research

Latest Cancer News and Research

New pathway for type 2 diabetes

Newly diagnosed type 2 diabetics tend to have one thing in common: obesity. Exactly how diet and obesity trigger diabetes has long been the subject of intense scientific research.

16 Aug 2011

Viewpoints: Health reform 'tax' vs. 'penalty'; super committee forecast; boomer tsunami

In a foolhardy indulgence of partisan ideology, Gov. Sam Brownback of Kansas is returning a $31.5 million federal grant that would have made his state a leader in technology development for the new federal health care law. … He joins other Republican governors willing to sell their constituents short in grandstanding against the health care law from statehouse pulpits.

16 Aug 2011

Caffeine in sunscreens may protect from skin cancer: Study

Studies have revealed that drinking caffeinated beverages reduces one’s chances of developing some types of cancer, including UV-associated skin cancer. Now, researchers propose a possible mechanism for this observation—the inhibition of a DNA repair pathway that sensitizes cells to death after sun exposure.

15 Aug 2011

Addiction to tanning

A new study reveals addiction of a new kind – addiction to tanning. Researchers have believed for several years that tanners exhibit similar behavior to alcoholics and drug addicts.

15 Aug 2011

‘Methyl magnet’ genes can cause family cancer risk

Medical researchers have discovered a new type of mechanism causing cancer susceptibility, showing that tiny changes in some anti-cancer genes can act as magnets to attract modifying “biochemical tags”, effectively switching them off and predisposing families to an increased risk of the disease.

15 Aug 2011

Faith influences health behaviors of American Muslim patients

The perceived role of God in illness and recovery is a primary influence upon the health care beliefs and behaviors of American Muslims, a first-of-its-kind study has discovered. Outreach and education efforts by the health care community can help address Muslim concerns and improve health care quality in this rapidly growing population, the report recommends.

12 Aug 2011

Targeted therapies that attack stem cell-like cancer cells can prevent spread of prostate cancer

A successful interdisciplinary project is underway between two research groups, in which senior researcher Rebecka Hellsten and Professor Anders Bjartell at the Faculty of Medicine's division for Urological Cancer Research, Sk-ne University Hospital in Malm-, and Professor Olov Sterner and Assistant Professor Martin Johansson at the Lund University division of Organic Chemistry recently published their latest research findings in the scientific online journal PLoS ONE.

12 Aug 2011

Thorne acquires global rights to Q-Cell, an advanced formulation Coenzyme Q10

Thorne Research, Inc., a leader in developing and manufacturing pure, high quality nutritional supplements marketed through licensed healthcare practitioners, has acquired exclusive global rights to market Q-Cell, an advanced formulation Coenzyme Q10 (CoQ10) supplement formerly marketed under the brand name Q-Best.

12 Aug 2011

Benefits of nanoparticle sunscreens outweigh risks

The most personal encounter that many consumers have had so far with the much-heralded field of nanotechnology is the topic of an article in the current edition of Chemical & Engineering News (C&EN), the American Chemical Society's weekly newsmagazine.

12 Aug 2011

Hysterectomy rates across Germany vary

Hysterectomy elevates the risk of stroke and coronary heart disease in young women when combined with the removal of both ovaries in the same operation. This fact provides the background for the epidemiological report by Andreas Stang and colleagues on hysterectomy rates in Germany, which appears in the current issue of Deutsches Ärzteblatt International.

12 Aug 2011

Galectin second quarter net loss increases to $3.9 million

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the second quarter and first six months, ended June 30, 2011.

12 Aug 2011

Advaxis completes ADXS-PSA prostate cancer construct pre-IND meeting with the FDA

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has completed a pre-IND (Investigational New Drug) meeting with the FDA on August 10 to discuss the development plan for ADXS-PSA, a construct for the treatment of prostate cancer.

12 Aug 2011

Soligenix second quarter revenues decrease to $406,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2011.

12 Aug 2011

Tanning beds may spur addictive neurological reward and reinforcement trigger

People who frequently use tanning beds may be spurred by an addictive neurological reward-and-reinforcement trigger, researchers at UT Southwestern Medical Center have found in a pilot study.

12 Aug 2011

Amorfix provides update on cancer therapeutic antibody programs

Amorfix Life Sciences Ltd., a product development company focused on diagnostics and therapeutics for misfolded protein diseases, provides an update on its cancer therapeutic antibody programs.

12 Aug 2011

Researchers to develop new prostate cancer therapy

Prostate cancer that has become resistant to hormone treatment and that does not respond to radiation or chemotherapy requires new methods of treatment. By attacking stem cell-like cells in prostate cancer, researchers at Lund University are working on a project to develop a new treatment option.

12 Aug 2011

Research team reports first genetic sequencing of urothelial carcinoma

In an article published online this week in Nature Genetics, a University of Colorado Cancer Center team in partnership with universities in China and Denmark reports the first genetic sequencing of urothelial (transitional) carcinoma, the most prevalent type of bladder cancer.

12 Aug 2011

Insight into how molecular motor proteins save energy

The transport system inside living cells is a well-oiled machine with tiny protein motors hauling chromosomes, neurotransmitters and other vital cargo around the cell. These molecular motors are responsible for a variety of critical transport jobs, but they are not always on the go. They can put themselves into "energy save mode" to conserve cellular fuel and, as a consequence, control what gets moved around the cell, and when.

12 Aug 2011

G-CSF therapy does not induce chromosomal instability in healthy stem cell donors

According to a study published in Blood, the Journal of the American Society of Hematology (ASH), researchers have reported that administration of granulocyte colony-stimulating factor (G-CSF), a drug that releases stem cells from the bone marrow into the blood, is unlikely to put healthy stem cell donors at risk for later development of abnormalities involving loss or gains of chromosomes that have been linked to hematologic disorders such as myelodysplastic syndromes (MDS) and acute myeloid leukemia.

12 Aug 2011

MYCN amplification can serve as a favorable prognostic indicator for neuroblastoma

Neuroblastoma, a malignant tumor that primarily affects infants and young children, is a leading cause of death for children with cancer. When amplification of the MYCN oncogene is found in the tumor, it usually indicates an aggressive tumor with rapid progression of the disease and a poor outcome. Thus MYCN amplification has come to be used as a prognostic indicator.

12 Aug 2011